A phase I trial of rV-PSA (vaccinia virus carrying PSA gene) was evaluated in 33 men with elevated PSA levels after radical prostatectomy, radiation therapy or the development of metastatic disease. This evidence concerns the gene KLK3 and metastatic neoplasm.